Weekly recap highlights Axsome Q2 revenue jump and PDUFA timeline
Axsome Therapeutics reported Q2 revenue of $218.4M, driven by AUVELITY, with strong Medicare 65+ sales and seven ongoing trials. The recap also notes an upcoming FDA PDUFA and Phase 3 readouts; Piper Sandler reiterated overweight with a $258 target.
Axsome Therapeutics, Inc. 4M, supported by AUVELITY and expanded indications. The company said Medicare 65+ sales were strong and that seven trials are ongoing, including an upcoming FDA PDUFA and Phase 3 readouts. Piper Sandler maintained an overweight rating and a $258 target.